Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2015-12-13 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 428.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the interest, and dates of transactions. This is a clear report of personal share transactions by a company director. The document length is 4004 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is a full financial report, earnings release, or other type of filing. Therefore, the appropriate classification is Director's Dealing (DIRS).
2015-12-13 English
Becoming a substantial holder 14 pages 790.8KB
Regulatory Filings
2015-12-06 English
Appendix 3B 9 pages 379.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically ordinary shares and employee options. It includes detailed information about the class, number, terms, issue price, purpose, and quotation of the securities. The document references compliance with ASX listing rules and the Corporations Act, indicating it is a formal regulatory announcement about capital changes. There is no financial performance data, management discussion, or audit information. The content aligns with announcements about new share issues or capital changes rather than a full report or other filing types. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive capital change filing.
2015-12-03 English
2015 AGM Chairman's Speech 4 pages 211.2KB
AGM Information Classification · 95% confidence The document is an ASX announcement titled 'ANNUAL GENERAL MEETING' and contains the Chairman's address and business updates presented at the 2015 Mayne Pharma Annual General Meeting. It includes introductions of board members, a summary of business performance, strategic investments, and a formal meeting agenda including voting on resolutions. The content is typical of materials shared during an AGM, focusing on company updates and shareholder engagement rather than detailed financial statements or regulatory filings. The length (9399 characters) and detailed narrative confirm it is the AGM presentation or materials rather than a brief announcement or a full annual report. Therefore, the document fits the category of AGM Information (AGM-R).
2015-11-25 English
2015 AGM CEO's Speech 5 pages 221.5KB
AGM Information Classification · 95% confidence The document is an ASX announcement titled 'ANNUAL GENERAL MEETING' and contains the CEO's address given at the AGM. It provides an update on company performance, strategic priorities, and operational segments, typical of presentations or materials shared during an AGM. There are no detailed financial statements or comprehensive annual report data, nor is it a brief announcement of voting results or a proxy solicitation. The content is consistent with AGM Information, as it is a speech or presentation given at the Annual General Meeting. The document length (11,548 characters) supports it being a full AGM presentation rather than a short announcement or report publication notice.
2015-11-25 English
Results of Meeting 2 pages 335.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication to the ASX Limited regarding the results of resolutions passed at the Mayne Pharma Group Annual General Meeting (AGM). It includes detailed voting results for each resolution, such as re-election of directors, adoption of remuneration report, share issuance, and remuneration increases. The presence of proxy voting details and the nature of the content clearly indicate this is an official declaration of voting results from a shareholder meeting. The document length is relatively short (2560 characters) and focuses solely on voting outcomes rather than the full AGM materials or presentations. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2015-11-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.